Last reviewed · How we verify

Verapamil HEXAL (verapamil)

Zealand University Hospital · FDA-approved active Small molecule

Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and decreasing heart rate, contractility, and blood pressure.

Verapamil blocks L-type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx and decreasing heart rate, contractility, and blood pressure. Used for Hypertension, Angina pectoris, Supraventricular tachycardia.

At a glance

Generic nameVerapamil HEXAL (verapamil)
Also known asVerapamil HEXAL
SponsorZealand University Hospital
Drug classCalcium channel blocker (non-dihydropyridine)
TargetL-type calcium channel
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Verapamil is a non-dihydropyridine calcium channel blocker that inhibits the inward movement of calcium ions through L-type calcium channels in the sinoatrial and atrioventricular nodes, as well as in vascular smooth muscle. This action slows conduction through the AV node, reduces myocardial contractility, and causes vasodilation, resulting in decreased heart rate and blood pressure. These effects make it useful for treating hypertension, angina, and certain arrhythmias.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: